BDX
BCAL DIAGNOSTICS LIMITED
$0.0900
▼ -1.10%
Market cap
$33M
Turnover
$79,843
Last price
$0.0900
Day change
-1.10%
Announcements
14
Range, past year
Open 0.081 · Low 0.052 · Now 0.090 · High 0.155
Open BDX in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.
BDX momentum and trend analysis
Our analysis
Independent analysis generated by Stock Trade Intelligence
as at 2026-10-13.
Momentum quality
44/100
Wyckoff phase
Accumulation34d
Trend stage
Neutral
1 Day
-1.1%
1 Week
-3.2%
1 Month
+26.8%
1 Year
+11.1%
RSI
61
Avg daily range
4.5%
BCAL DIAGNOSTICS LIMITED scores 44 out of 100 for momentum quality, a reading rated very low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Neutral.
On the Wyckoff cycle it sits in Accumulation, where it has been for 34 trading days. The weekly timeframe reads Accumulation, which agrees with the daily view.
Against the wider market it is currently outperforming and the institutional accumulation signal reads low.
What stands out
- Fresh trend age (24 days)
- Volume 1.5× 60-day avg
- RSI in healthy zone (61)
Points to watch
- 60d drawdown -33.3%
- Thin liquidity
- Risk rating: Very High
- Composite downside risk elevated
BDX announcements
Recent price-sensitive releases.
- 2026-09-30 BREASTESTplus 2 clinically validated Progress Report
- 2026-09-23 BCAL Introduces Avantect Multi-Cancer Early Detection Test Progress Report
- 2026-08-28 Appendix 4E and Annual Report to shareholders Annual Report | Top 20 shareholders | Preliminary Final Report | Full Year Accounts | Full Year Audit Review | Full Year Directors' Statement | Full Year Directors' Report
- 2026-08-26 BCAL Takes Interest in Genetic Signatures to 18.46% Security holder details - Other
- 2026-08-21 BCAL Secures Funding for FY2027 Update Periodic Reports - Other | Issued Capital - Other
- 2026-07-30 Quarterly Activities/Appendix 4C Cash Flow Report Commitments Test Entity - Fourth Quarter Activity Report | Commitments Test Entity - Fourth Quarter Cashflow Report
- 2026-07-02 BCAL to Acquire Shares in Genetic Signatures
More Health Care stocks
Most traded in the same sector.